Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Mar 31
- 1 min read
30/03/2026
Aurinia Pharmaceuticals announced acquisition of Kezar Life Sciences (Ref)
Aurinia Pharmaceuticals entered into a definitive merger agreement to acquire Kezar life sciences for $6.955 per share in cash, plus one non-transferable Contingent Value Right (CVR), which represents the right to receive:
Potential payments from the ongoing development or disposition of zetomipzomib (immunoproteasome inhibitor) being evaluated for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus
Certain proceeds relating to Kezar’s collaboration with Everest Medicines and Kezar’s sale of its Sec61‑based discovery and development to Enodia Therapeutics
100% of Kezar’s closing net cash in excess of $50 million, net of certain post-closing CVR-related expenses
Tang Capital Partners, LP (~9.0% of Kezar shares) signed a tender and support agreement to tender its shares in favor of the deal, the deal was expected to close in Q2 2026
Savara announced EMA validation of MAA for MOLBREEVI in autoimmune PAP (Ref)
Savara announced that the European Medicines Agency (EMA) had validated the submission of the MOLBREEVI Marketing Authorization Application (MAA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)
EMA review of MOLBREEVI MAA was initiated, with a decision expected in Q1 2027
The MOLBREEVI Biologics License Application (BLA) was under priority review with the US FDA, with an action date of August 22, 2026
